Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Diagnosis of prostatitis

Prostate cancer prevention

Prostate Cancer and Exercise

What is medical castration?

Cryosurgery for prostate cancer

Precancerous conditions of the prostate

Life after prostate cancer treatment

Prostate Cancer Staging

Prostate Cancer Symptoms

Recent Genetic Breakthroughs in Prostate Cancer Research

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

See more featured articles »

Causes of benign prostatic hyperplasia

Prostate cancer alternative and complementary therapies

What is TURP?

Prostate Cancer Epidemiology

What is the PCA3 Test?

Treatment of Benign Prostatic Hyperplasia (BHP)

Prostate Cancer Research

Breakthroughs in Prostate Cancer Treatments

The International Prostate Symptoms Score (IPSS)

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

Causes of prostatitis

Can Curcumin Prevent or Treat Prostate Cancer?

What is Prostatitis?

Single Nucleotide Polymorphisms and Prostate Cancer

Prostate Cancer and Genetics

Prostate Cancer Epidemiology Worldwide

Radiation therapy for prostate cancer

Prostate Cancer Cell Dormancy and Activation

Prostate Cancer and Diet

Treatment of prostatitis

What is the PSA Test?

PSA Test in Men Who Have Been Treated for Prostate Cancer

Prostate Cancer Risk Factors

Differentiating between prostate cancer and prostate enlargement

Hormonal therapy for prostate cancer

Prostate Biopsy

What Should You Avoid Before a PSA Test?

Prostate Cancer Screening

Prostate cancer complications

Prostatitis symptoms

What is the Gleason Score?

Prostate Cancer Partin Tables

Rectal Examination for Prostate Cancer

Symptoms of Benign Prostatic Hyperplasia (BHP)

PSA False Positive and False Negative Results

Gold Nanoparticles Use in Prostate Cancer

Prostate Cancer Diagnosis

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer Questions

Prostate Cancer Treatment

What is benign prostatic hyperplasia?

Types of PSA Test

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Survival rates of prostate cancer

Choosing the best treatment of prostate cancer - by stage

The Prostate

What is Prostatectomy?

Brachytherapy for Prostate Cancer

Latest Prostate Cancer News and Research

Talc not contaminated with asbestos shows no link to cancer

In a systematic review and meta-analysis, researchers found that occupational exposure to talc that is not contaminated with asbestos is not associated with an increase in the risk of lung cancer, mesothelioma, or laryngeal cancer.

10 Apr 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

New technique can simultaneously treat lung cancer and muscle-wasting condition

Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it.

6 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

PSMA therapy may postpone hormone treatment in prostate cancer patients

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is also effective in an earlier stage of the disease.

30 Mar 2026

ATLAS platform enables realistic study of metastatic cancer clusters

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer cells encounter as they travel through the bloodstream.

26 Mar 2026

Men show major gaps in male fertility knowledge, study finds

A study of 156 adult men found that knowledge about male fertility was generally low across both medical and lifestyle-related topics, with only 5 of 25 questions answered correctly by most respondents. Older men, those with a medical background, and those with suspected or treated infertility tended to score higher, while supplement use was common despite limited fertility literacy.

26 Mar 2026

Estradiol patches as effective as injections for locally advanced prostate cancer

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL (University College London) researchers.

25 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

Detailed cell atlas reveals earliest changes in prostate cancer

Prostate cancer affects one in five Australian men, making it the most common cancer in the country.

25 Mar 2026

Systematic review identifies stress-induced biological triggers in oncology

Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses.

25 Mar 2026